

Neuroscientific Appoints Clinician Dr Cole as Chief Medical Officer

NeuroScientific Biopharmaceuticals Ltd (ASX: **NSB**) (“**NeuroScientific**” or “**the Company**”) is pleased to announce the appointment of Dr Catherine Cole as its Chief Medical Officer with immediate effect.

Dr Cole steps into the role at a key development stage for the Company as the Special Access Scheme (SAS) program in Fistulas in Crohn’s is underway, with interim results anticipated later this year. Dr Cole has had a very impressive clinical career in paediatric and adolescent haematology and oncology, including bone marrow transplantation, and is recognised as a leading physician in Australia and internationally.

Dr Cole holds or has held the following roles:

- Head of Haematology and Oncology at Princess Margaret Hospital (PMH)/Perth Children’s Hospital,
- Director of Hematopoietic Stem Cell Transplantation at PMH for Children
- Inaugural Professor of Paediatric Haematology and Oncology at UWA
- Head of Paediatric Haematology/Oncology and Bone Marrow Transplantation at SIDRA Medicine in Doha, Qatar
- Transfusion Medical Specialist for Lifeblood (WA)
- Haematologist for Saturn Laboratories (WA)
- Member of WA Human Research Ethics Committee
- Head of the School of Biomedical Sciences at University of Western Australia (UWA)
- Director of Laboratory Haematology PathWest (WA)
- Co-Director of the Children’s Cancer Centre Telethon Kids Institute (WA)
- Principal Investigator Children’s Oncology Group in North America
- Member of the Advisory Group for Prescription Medicines of the Therapeutic Goods Administration (TGA)
- Member of the Pharmaceutical Benefits Advisory Committee (PBAC) - Australian Department of Health
- Member of Economics sub-committee of PBAC - Australian Department of Health

Dr Cole commented *“the growing global recognition of mesenchymal stromal cells (MSC’s) as a treatment for immune-mediated conditions particularly Graft Versus Host Disease (GVHD) underscores the significant therapeutic potential of this approach. MSC’s act by modulating the immune system, reducing inflammation, promoting immune tolerance and facilitating tissue repair. In my clinical experience, the StemSmart™ MSCs have been highly effective in treating my patients with severe GVHD. I look forward to helping expand access to life-changing therapy for patients affected by a range of immune and inflammatory disorders”*

Chair Mr Rob McKenzie said, *"We are very fortunate that Cathy is joining at this key time in the Company's evolution. Her vast experience and leadership will greatly strengthen our management team as we progress our SAS fistulas in Crohn's program and make plans for future growth. I look forward to working closely with Cathy as she brings a wealth of experience in patient treatment, clinical trials and navigating the regulatory and reimbursement systems."*

This announcement is authorised by the Board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Paul Fry
Executive Director
pfry@stemsmart.com.au
+61 (0) 422 001 188

Chris Achurch
Company Secretary
chris@westarcapital.com.au
+61 8 6268 2641

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a biotechnology company focused on the development of novel therapeutics targeting immune-mediated inflammatory disorders. The Company's research is centred on modulating pathological immune responses involved in chronic and degenerative conditions, particularly where current therapeutic options demonstrate limited efficacy or durability. NSB applies advanced preclinical and translational strategies to support the development of first-in-class or best-in-class biologics addressing significant unmet clinical need.

Targeting Crohn's Disease with StemSmart™ Technology

Following the acquisition of Isopogen WA Ltd, NSB is prioritizing the application of its proprietary StemSmart technology through a SAS program targeting fistulising Crohn's disease—a severe and treatment-resistant form of the condition. If early outcomes from this access program are favourable, the Company intends to progress to a Phase 1/2 clinical trial to further evaluate safety and preliminary efficacy. This initiative aligns with NSB's broader strategy to obtain regulatory and reimbursement approval for its MSC therapy both in Australia and internationally, with the goal of making the treatment available to patients with fistulising and refractory Crohn's disease, for whom current therapies remain inadequate.

About EmtinB™

EmtinB™ is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB™ is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body's innate immune response to cell injury. Our preclinical research has established that EmtinB™ is highly specific and selective for its target receptor, safe and well tolerated at high concentrations.